the nanoemulsion of the present invention is a slightly yellow , transparent or translucent composition , which comprises oil droplets of an average size of less than 200 nanometers in diameter , or more preferably , less than 100 nm . the nanoemulsion is stable and has an excellent long - term stability ( example 6 ). chemically it maintains the integrity of vitamin k1 and physically , it remains transparent or translucent , maintaining the same nanometer droplet size upon prolonged storage ( e . g ., 24 months ). more particularly , the nanoemulsion is characterized by high light transmittance at 600 / 750 nm and small droplet size , even after storage at 25 ° c . for 6 months or after a freeze - thaw treatment . such stability properties , which are very advantageous for a commercially feasible drug product , are not found in any aqueous solution or emulsion compositions disclosed in the prior art . biologically , the nanoemulsion is non - allergenic , does not cause hypersensitivity or anaphylactic reactions , is non - hemolytic and is bioequivalent to pie - usp . the term “ nanoemulsion ” used herein includes an oil - in - water emulsion having oil droplets that are exceedingly small in size , i . e ., less than 200 nm or preferably 100 nm , and having a high transparency with light transmittance at 600 nm or 750 nm of no less than 20 % or preferably 50 %. in certain embodiments , the oil droplet size is about 75 nm - 200 nm , such as 75 nm to 150 nm , or 75 nm to 115 nm . in certain embodiments , the oil droplet size is about 75 nm , 80 nm , 85 nm , 90 nm , 95 nm , 100 nm , 105 nm , 110 nm , 115 nm , 120 nm , 125 nm , 130 nm , 135 nm , 140 nm , 145 nm , 150 nm , 155 nm , 160 nm , 165 nm , 170 nm , 175 nm , 180 nm , 185 nm , 190 nm , 195 nm , or 200 nm . in certain embodiments , a nanoemulsion of this invention solubilizes the lipophilic vitamin k presumably in those droplets . physically , a nanoemulsion has significant differences compared to regular oil - in - water emulsions . for example , a nanoemulsion is transparent ( i . e ., with a high t600 / t750 light transmittance value ) and has a solution - like appearance whereas a regular emulsion is milky - white and opaque with t600 / t750 & lt ; 20 %. the average droplet size of a nanoemulsion is much below the average droplet size of a regular oil - in - water emulsion , for which the average droplet diameter is usually greater than 300 - 400 nm . and finally , the nanoemulsion exhibits far better stability than a regular oil - in - water emulsion with minimal changes in the transparency or droplet size after being stored at 25 ° c . or 2 - 8 ° c . for 6 months or after a freeze - thaw treatment . most surprisingly , in certain preferred embodiments the nanoemulsion of this invention is bioequivalent to the commercial product pie - usp — a property that no other emulsion has yet matched . “ phytonadione injectable emulsion , usp ” refers to a sterile , aqueous dispersion of phytonadione . prior to feb . 1 , 2005 , it was labeled as “ phytonadione injection , usp ”. merck & amp ; co . initially developed pie - usp under the brand name of “ aquamephyton ®” which contains 10 mg / ml phytonadione , 70 mg / ml polyoxyethylated fatty acid derivative ( cremophor ), 37 . 5 mg / ml , 9 mg / ml benzyl alcohol and water . it is worth noting that phytonadione injectable emulsion , usp does not contain any oil in its composition and is technically not an oil - in - water emulsion despite what its name suggests . rather , using a strict physical chemistry definition , pie - usp should be defined as an aqueous solution , since all components are dissolved in water . as an aqueous solution , pie - usp is sensitive to freezing stress . upon freezing and thawing , aquamephyton ® or its generic equivalent will form two phases with the cremophor separating out . a phase separated preparation is unsafe for intravenous injection as its larger droplets could form blockages in capillaries , resulting in an embolism . therefore , storage conditions for pie - usp must be carefully controlled to prevent accidental freezing . in contrast , in certain preferred embodiments the nanoemulsion of this invention is robust and retains its properties after a freeze - and - thaw cycle . that is , the average droplet size or the light transmittance of the nanoemulsion of the current invention remained essentially unchanged after a freeze - and - thaw stress . in certain preferred embodiments , the nanoemulsion of this invention , being an oil - in - water emulsion , is therefore different from pie - usp in its composition , physical form and stability after a freeze - and - thaw cycle ( example 12 ). the term “ vitamin k ” as used herein includes a group of lipophilic , hydrophobic vitamins that are needed for the post - translational modification of certain proteins , mostly required for blood coagulation . chemically , they are 2 - methyl - 1 , 4 - naphthoquinone derivatives . vitamin k 1 is also known as phylloquinone or phytomenadione ( also called phytonadione ), and vitamin k 2 is also known as menaquinone or menatetrenone . there are three synthetic forms of vitamin k , vitamins k 3 , k 4 , and k 5 , which are used in many areas including the pet food industry ( vitamin k 3 ) and for inhibiting fungal growth ( vitamin k 5 ). the term “ light transmittance (%)” as used herein is a measurement of transparency of the nanoemulsion and is defined as the fraction of incident light at a specified wavelength ( i . e ., 600 nm ) that passes through a sample . it is calculated using the following equation : where i 0 is the intensity of the incident light and i is the intensity of the light coming out of the sample and t λ is transmittance . the t λ value can be readily measured by a uv - visible spectrophotomer at a fixed wavelength . a visible wavelength such as 600 or 750 nm is commonly used to obtain the t600 or t750 values . the light transmittance value of an emulsion is directly related to its droplet size and can be used to differentiate certain preferred embodiments of the nanoemulsion of this invention from a regular emulsion . for a conventional emulsion such as milk or a fat emulsion for intravenous injection such as intralipidt ™, the light transmittance value measured at 600 nm / 750 nm wavelength is generally less than 5 - 10 % ( such as up to 0 . 5 , 1 , 2 , 3 , or 4 %; or alternatively , up to 5 , 6 , 7 , 8 , 9 , or 10 %), which is due to the light - reflecting white and opaque properties of these emulsions . the nanoemulsion of the current invention is , however , characterized by a very high transmittance of greater than 20 % and is nearly transparent ( fig1 ). the term “ cremophor ” as used herein is the registered trademark of basf corp . for its version of polyethoxylated castor oil . it is prepared by reacting 35 moles of ethylene oxide with each mole of castor oil . the resulting product is a mixture of castor oil molecules with differing degrees of polyethoxylation ( cas number 61791 - 12 - 6 ). cremophor is a synthetic , nonionic surfactant and its pharmaceutical utility comes from its ability to stabilize emulsions of nonpolar materials in aqueous systems . cremophor is an excipient or additive in drugs . cremophor and some other surfactants of high hlb values ( meaning soluble in water ) such as polysorbate 80 are known to cause hypersensivity or anaphylaxis when injected intravenously . such allergic reactions are well documented for a number intravenously - administered drugs that contain cremophor or polysorbate 80 , such as taxol for the latter . the term “ bioequivalent ” as used herein includes a plasma concentration - over - time pharmacokinetic ( pk ) profile that coincides with the pk profile of a reference drug . as used herein , the term includes the coinciding and nearly identical pk profile from a vitamin k 1 nanoemulsion composition of certain preferred embodiments of this invention and the corresponding pk profile for pie - usp following an intravenous , intramuscular or subcutaneous injection in a selected animal or human model ( e . g ., see fig4 and 5 ). the nanoemulsion composition of this invention comprises a vitamin k at from about 0 . 1 to 2 % ( such as about 0 . 18 , 0 . 2 , 0 . 22 , 0 . 5 , 0 . 8 , 1 . 0 , 1 . 2 , 1 . 5 , 1 . 8 , or 2 %), preferably from about 0 . 2 to 1 % ( such as about 0 . 18 , 0 . 2 , 0 . 22 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 . 0 or 1 . 1 %), a phospholipid at a phospholipid - to - vitamin k weight ratio of about 13 : 1 to 25 : 1 ( such as 13 : 1 , 14 : 1 , 15 : 1 , 16 : 1 , 17 : 1 , 18 : 1 , 19 : 1 , 20 : 1 , 21 : 1 , 22 : 1 , 23 : 1 , 24 : 1 , or 25 ; 1 ), and an oil at no more than 1 % by weight of the emulsion weight ( such as up to about 1 , 0 . 9 , 0 . 8 , 0 . 7 , 0 . 6 , 0 . 5 , 0 . 4 , 0 . 3 , 0 . 2 , or 0 . 1 %). the terms “ a ,” “ an ,” or “ the ” as used herein not only includes aspects with one member , but also aspects with more than one member . for example , an embodiment including “ a phospholipid and a triglyceride oil ” should be understood to present aspects with at least a second phospholipid , at least a second triglyceride oil , or both . the term “ about ” as used herein to modify a numerical value indicates a defined range around that value . if “ x ” were the value , “ about x ” would generally indicate a value from 0 . 8x to 1 . 2x , and more preferably , 0 . 9x to 1 . 1x . any reference to “ about x ” specifically indicates at least the values x , 0 . 90x , 0 . 91x , 0 . 92x , 0 . 93x , 0 . 94x , 0 . 95x , 0 . 96x , 0 . 97x , 0 . 98x , 0 . 99x , 1 . 01x , 1 . 02x , 1 . 03x , 1 . 04x , 1 . 05x , 1 . 06x , 1 . 07x , 1 . 08x , 1 . 09x , and 1 . 10x . thus , “ about x ” is intended to teach and provide written description support for a claim limitation of , e . g ., “ 0 . 98x .” when the quantity “ x ” only includes whole - integer values ( e . g ., “ x carbons ”), “ about x ” indicates from ( x − 1 ) to ( x + 1 ). in this case , “ about x ” as used herein specifically indicates at least the values x , x − 1 , and x + 1 . when “ about ” is applied to the beginning of a numerical range , it applies to both ends of the range . thus , “ from about 5 to 20 %” is equivalent to “ from about 5 % to about 20 %.” when “ about ” is applied to the first value of a set of values , it applies to all values in that set . thus , “ about 7 , 9 , or 11 %” is equivalent to “ about 7 %, about 9 %, or about 11 %.” in general , embodiments described herein that include chiral compounds may include embodiments with the racemic form or embodiments enriched in the d - or l - enantiomer thereof . the term “ or ” as used herein should in general be construed non - exclusively . for example , an embodiment of “ a composition comprising a or b ” would typically present an aspect with a formulation comprising both a and b . “ or ” should , however , be construed to exclude those aspects presented that cannot be combined without contradiction ( e . g ., a formulation ph that is between 9 and 10 or between 7 and 8 ). generally , when a percentage range is taught , it incorporates all full or partial percentages in between ( i . e ., within the bounds of the range ). for example , a percentage range of 5 to 20 % would also teach inter alia the specific values of 7 . 15 % and 17 %. a percentage range of about 0 . 5 to 2 % would also teach inter alia the specific values of 1 . 37 %, 1 . 2 %, and 0 . 63 %. the term “ soybean oil ” as used herein includes refined oil extracted from soybean . for injection use , such oil must pass certain quality specifications including purity , microbiological and endotoxin limits , meeting certain compendial standards and be manufactured in a facility meeting cgmp standards . in certain embodiments , the concentration of the oil is no more than 1 %, such as about 0 , 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , or 1 . 0 %. in certain embodiments , other vegetable oils including , but not limited to , almond oil , borage oil , black currant seed oil , corn oil , safflower oil , soybean oil , sesame oil , cottonseed oil , peanut oil , olive oil , rapeseed oil , coconut oil , palm oil , canola oil , etc . may be used as well . the specific type of vegetable oil used ( e . g ., soy bean oil , corn oil , or safflower oil , etc .) is not critical , so long as it is safe , well tolerated , pharmaceutically acceptable , chemically stable and can be formed into droplets having a desired size range . the term “ medium chain triglyceride ” ( mct ) as used herein includes another class of triglyceride oil that can be either naturally derived or synthetically produced . mcts are made from fatty acids that are usually about 8 to about 12 carbons in length . like vegetable oils , mcts have been used extensively in injectable emulsion preparations as a source of calories for patients requiring parenteral nutrition . such oil is commercially available as miglyol 812 from sasol gmbh , germany , crodamol gtcc - pn from croda , inc . of parsippany , n . j ., or neobees m - 5 oil from pvo international , inc ., of boonton , n . j . other low - melting medium chain oils may also be used in the present invention . in certain embodiments , the concentration of mct is no more than 1 %, such as about 0 , 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 . 0 %). in certain embodiments , the vegetable oil to mct oil ratio is within a range of about 2 : 1 to about 1 : 2 ( such as about 2 : 1 , 1 . 9 : 1 , 1 . 8 : 1 , 1 . 7 : 1 , 1 . 6 : 1 , 1 . 5 : 1 , 1 . 4 : 1 , 1 . 3 : 1 , 1 . 2 : 1 , 1 . 1 : 1 , and 1 : 1 ) and preferably about 1 : 1 . the term “ phospholipid ” as used herein includes a triester of glycerol with two fatty acids and one phosphate ion . exemplary phospholipids useful in the present invention include , but are not limited to , phosphatidyl chlorine , lecithin ( a mixture of choline ester of phosphorylated diacylglyceride ), phosphatidylethanolamine , phosphatidylglycerol , phosphatidic acid with about 4 to about 22 carbon atoms , and more generally from about 10 to about 18 carbon atoms and varying degrees of saturation . the term “ phospholipid ” used herein can be either a single phospholipid or a mixture of several phospholipids . the phospholipids useful in the present invention can preferably be of natural origin for enhanced safety . naturally occurring phospholipids include soy lecithin , egg lecithin , hydrogenated soy lecithin , hydrogenated egg lecithin , sphingosine , gangliosides , and phytosphingosine and combinations thereof . phospholipids can also be synthesized and the common synthetic phospholipids may include but are not limited to diacylglycerols , phosphatidic acids , phosphocholines , phosphoethanolamines , phosphoglycerols , phosphoserines , lysophospholipids , and pegylated phospholipids . in certain embodiments , the concentration of phospholipid is 4 to 25 %, such as about 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , or 25 %). in certain embodiments , the nanoemulsion of the present invention may further contain pharmaceutically acceptable additives including , but not limited to , acidifying , alkalizing , buffering , chelating , complexing and solubilizing agents , antioxidants and antimicrobial preservatives , suspending and / or viscosity modifying agents , tonicity modifying agents , cryo - protectants , and other biocompatible materials or therapeutic agents . in certain embodiments , such additives assist in stabilizing the nanoemulsion and rendering sufficient shelf life to the compositions of the present invention . in certain embodiments , the nanoemulsion of the present invention has an osmolality of approximately 300 to 500 mosm and may include potassium or sodium chloride , trehalose , sucrose , sorbitol , glycerol , mannitol , polyethylene glycol , propylene glycol , albumin , amino acid and mixtures thereof . the term “ antioxidants ” as used herein preferably includes metal ion chelators and / or reducing agents that are safe to use in an injectable product . a metal ion chelator works as an antioxidant by binding to metal ions and thereby reduces the catalytic effect of metal ions on the oxidation reaction of the test substance . metal chelators that are useful in certain embodiments of this invention may include edta , glycine and citric acid or salts thereof . reducing agents achieve their antioxidant effect by reacting with oxidizing agents in competition with test substance or by converting the oxidized test substance back to the original test substance in the reduced form . the reducing agents useful in certain embodiments of this invention include , but are not limited to , methionine , cysteine , glutathione , ascorbic acid or salts thereof , ascorbyl palmitate , sodium metabisulfite , propyl gallate , butylated hydroxyanisole , butylated hydroxytoluene , tocopherol , histidine , amino acids or salts thereof , reducing sugars or any mixtures thereof . the term “ cryo - protectant ” as used herein includes any of the safe and biocompatible agent ( s ) that protect the nanoemulsion during freezing by keeping the sub - micron size droplets separate in the surrounding milieu . the cryo - protectants useful for certain embodiments of the present invention include , but are not limited to , monosaccharides , disaccharides , polysaccharides , propylene glycol , polyethylene glycol , glycerol , poly - ols , dextrins , cyclodextrins , starches , cellulose and cellulose derivatives , proteins , peptides , amino acids , sodium chloride , polyvinypyrrolidone , or mixtures thereof . for instance , in certain embodiments , the cryo - protectant is mannitol , sorbitol , xylitol , lactose , fructose , xylose , sucrose , trehalose , mannose , maltose , dextrose , dexstrane , or a mixture thereof . in certain embodiments , the cryo - protectant is sucrose , a combination of sucrose and mannitol , or a combination of sucrose and trehalose . in certain embodiments , the formulations of the present invention do not comprise gum acacia . the term “ injectable ” as used herein includes the acceptance of an ingredient by a drug regulating authority ( e . g ., the us fda ) permitting its use in an injection drug . in certain embodiments , the present compositions are both chemically and physically stable . a composition is “ chemically stable ” if the drug , e . g ., vitamin k , in the composition is not substantially chemically degraded after storage under appropriate conditions for at least one month . in certain embodiments , the concentration of the intact vitamin k in the composition is reduced by less than about 5 % under appropriate storage conditions ( e . g ., at − 20 ° c ., 2 - 8 ° c ., or at room temperature ) for at least 6 months . as used herein , a nanoemulsion composition is “ physically stable ” if it can be stored under appropriate conditions for at least 6 months without an increase in its average particle size by more than 100 %, or without evidence of phase separation , creaming , or particle aggregation . in certain embodiments , the average size of particles of a composition of the present invention does not increase by more than about 10 %, 20 %, 25 %, 30 %, 40 %, 50 %, 75 %, or 100 % under appropriate storage conditions ( e . g ., at − 20 ° c ., 2 - 8 ° c ., or room temperature ) for at least 6 months . the compositions described herein are especially useful for treating blood coagulation disorders including ( 1 ) prophylaxis and therapy of hemorrhagic disease of the newborn ; ( 2 ) anticoagulant - induced prothrombin deficiency caused by coumarin or indanedione derivatives ; ( 3 ) hypoprothrombinemia due to antibacterial therapy ; ( 4 ) hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k ; and ( 5 ) other drug - induced hypoprothrombinemia . acquired coagulation disorders are the result of conditions or diseases , such as vitamin k deficiency , liver disease , disseminated intravascular coagulation ( dic ), or development of circulation anticoagulants . the defects in blood coagulation are the result of secondary deficiencies in clotting factors caused by the condition or disease . for example , production of coagulation factors from the liver is often impaired when the liver is in a diseased state . along with decreased synthesis of coagulation factors , fibrinolysis becomes increased and thrombocytopenia ( deficiency in platelets ) is increased . decreased production of coagulation factors by the liver also can result from fulminant hepatitis or acute fatty liver of pregnancy . such conditions promote intravascular clotting which consumes available coagulation factors . the compositions provided herein can be used in the treatment of acquired coagulation disorders in order to alleviate deficiencies in blood clotting factors . patients undergoing anticoagulant therapies for the treatment of conditions , such as thromboembolism , can exhibit bleeding episodes upon acute administration of anticoagulants or develop hemorrhagic disorders as a result long term usage of such therapies . the compositions provided herein are useful for treatments for such bleeding episodes which typically include administration of procoagulants . the compositions provided herein can be used in treatments to control bleeding episodes in patients with acquired bleeding disorders due to anticoagulant treatments . the invention will now be described in greater detail by reference to the following non - limiting examples . a nanoemulsion containing 0 . 2 % vitamin k1 was prepared using the following composition and procedure : f - 1 composition ingredient % w / w phytonadione 0 . 2 soybean oil 0 . 5 medium chain triglyceride 0 . 5 soy lecithin 5 sucrose 10 benzyl alcohol 0 . 9 de - ionized water , qs to 100 * phospholipid - to - vitamin k weight ratio = 25 : 1 ** oil concentration = 1 % by weight 1 . weigh out phytonadione , soybean oil , medium chain triglyceride , phospholipon 90g and benzyl alcohol in a clean container . sonicate and gently heat to dissolve all solids to obtain a clear yellow solution . 2 . weigh out sucrose and de - ionized water into another clean container . mix well to dissolve all solids to obtain a clear colorless solution . 3 . mix the above 2 solutions by agitation to form a crude emulsion and adjust ph to between 6 - 7 using 1n hcl or naoh . 4 . homogenize the crude emulsion to a nanoemulsion by using a microfluidizer until the average droplet size , as determined by laser light scattering , is less than 100 nm . 5 . filter the nanoemulsion through a 0 . 22 μm filter to sterilize the nanoemulsion . perform this procedure under a nitrogen atmosphere . the f - 1 nanoemulsion thusly prepared is a slightly yellow and transparent / translucent solution . a nanoemulsion containing 0 . 2 % vitamin k1 was prepared using the following composition and the procedure as described in example 1 : ** oil concentration = 1 % by weight . the f2 nanoemulsion prepared is a slightly yellow and transparent / translucent solution . a nanoemulsion containing 1 % vitamin k1 was prepared using the following composition and the procedure as described in example 1 : methionine or ascorbic acid may be optionally added the above compositions . a nanoemulsion containing vitamin k2 ( menaquinone ) was prepared using the following composition and the procedure as described in example 1 . a nanoemulsion containing vitamin k2 ( menaquinone ) was prepared using the following composition and the procedure as described in example 1 . a lot of f - 1 nanoemulsion ( lot # 111 - 1 - 11 ) was prepared according to example 1 and tested for long - term stability . the stability tests included ( a ) appearance , ( b ) light transmittance @ 600 nm , ph , vitamin k1 assay and purity by hplc , and average droplet size as determined by laser light scattering . another lot of nanoemulsion ( lot # 111 - 1 - 24 ) was prepared according to example 2 and tested for long - term stability . the stability tests include ( a ) appearance , ( b ) light transmittance @ 600 nm , ph , vitamin k1 assay and purity by hplc , and average droplet size as determined by laser light scattering . appearance : storage initial ( t0 ) 1 month 2 month 3 month 9 month 18 month 24 month 2 - 8 ° c . yellow , clear same as same as same as same as same as same as and uniform t0 t0 t0 t0 t0 t0 25 ° c . solution . same as same as same as no slightly slightly no visible t0 t0 t0 change opaque opaque 40 ° c . oil droplets same as same as same as not not not or solid t0 t0 t0 tested tested tested particles storage time 0 1 month 2 month 3 month 9 month 18 month 24 month light transmittance @ 600 nm 2 - 8 ° c . 81 . 3 % 79 . 7 % 80 . 5 % 72 . 7 % 71 . 9 % 62 . 4 % 61 . 7 % 25 ° c . 66 . 6 % 64 . 7 % 66 . 2 % 70 . 1 % 73 . 4 % 74 . 3 % 40 ° c . 59 . 9 % 61 . 5 % 63 . 6 % not not not tested tested tested ph 2 - 8 ° c . 7 . 09 6 . 97 6 . 64 6 . 51 6 . 45 6 . 41 6 . 38 25 ° c . 6 . 87 6 . 65 6 . 58 6 . 31 6 . 38 6 . 45 40 ° c . 6 . 70 6 . 69 6 . 61 not not not tested tested tested vitamin k1 assay by hplc in mg / ml (% of assay over the initial assay value ) 2 - 8 ° c . 1 . 94 1 . 96 1 . 96 2 . 11 1 . 91 1 . 94 1 . 91 ( 101 . 4 ) ( 101 . 1 ) ( 108 . 8 ) ( 98 . 5 ) ( 100 ) ( 98 . 5 ) 25 ° c . 1 . 94 1 . 89 1 . 96 1 . 72 1 . 63 1 . 61 ( 100 . 1 ) ( 97 . 7 ) ( 101 . 2 ) ( 88 . 7 ) ( 84 . 0 ) ( 83 . 0 ) 40 ° c . 1 . 91 1 . 73 1 . 79 not not not ( 98 . 9 ) ( 89 . 3 ) ( 92 . 3 ) tested tested tested chromatogram purity , 330 nm 2 - 8 ° c . 99 . 9 % 94 . 5 % 94 . 7 % 97 . 3 % 98 . 6 % 93 . 5 % 85 . 9 % 25 ° c . 94 . 6 % 94 . 3 % 96 . 4 % 88 . 6 % 92 . 7 % 85 . 2 % 40 ° c . 96 . 0 % 94 . 5 % 95 . 1 % not not not tested tested tested average droplet size ( nm in diameter ) by laser light scattering 2 - 8 ° c . 83 . 9 nm 86 . 4 85 . 3 107 98 . 4 105 108 25 ° c . 119 112 132 119 120 128 40 ° c . 136 136 159 not not not tested tested tested conclusion : f - 1 and f - 2 are physically and chemically stable at 2 - 8 and 25 deg c . methods : using the standard rabbit marginal ear vein model a lot ( lot # 111 - 1 - 24 ) of f - 2 nanoemulsion containing vitamin k1 prepared according to example 2 was infused at the maximum clinical concentration ( 0 . 6 mg / ml ) at a rate of 1 . 0 ml / min with a dose of 18 mg per rabbit for total eight male new zealand white rabbits . injections were given once a day for three consecutive days . the control group was infused with a 5 % dextrose solution for injection ( d5w ). results : during the infusion , the animals remained quiet and exhibited steady breathing . after each infusion , no edema or redness was observed at the injection site . forty - eight hours after the last infusion , animals were sacrificed and the marginal ear vein with surrounding tissue from the downstream section of the injection site was removed for histopathologic examination . no tissue inflammation , denaturation , necrosis or other signs of irritation was observed ( fig3 ). conclusion : the vitamin k1 nanoemulsion ( f - 2 ) does not cause vein irritation and meets the requirement for injection site safety . method : visual examination of hemolysis or aggregation , in vitro , in 2 % rabbit red blood cells ( rbc ) suspended in a normal saline solution containing the f - 2 vitamin k1 nanoemulsion ( lot # 111 - 1 - 24 ) prepared according to example 2 . the f - 2 nanoemulsion was adjusted to a concentration used clinically and mixed with a 2 % rabbit rbc suspension at various ratios ( see table below ); the mixtures were then incubated at 37 ° c . for 3 hours and observed for hemolysis and aggregation . pie - usp was evaluated in the same way for comparison . results : no hemolysis or aggregation was observed at any mixing ratio or the clinically used concentration for the f - 2 nanoemulsion ( up to 1 mg / ml vitamin k ). in contrast , pie - usp ( a generic formulation of aquamephyton ) was hemolytic at higher concentrations ( 0 . 16 , 0 . 2 , 0 . 4 , 0 . 6 , and 1 mg / ml , tubes # 4 to # 8 ) ( fig4 ), consistent with its known propensity to be locally irritating following subcutaneous or intramuscular injection . conclusion : vitamin k1 nanoemulsion ( f - 2 ) prepared according to this invention is non - hemolytic at up to 1 mg / ml vitamin k and pie - usp is hemolytic as low as 0 . 16 mg / ml in the rabbit rbc assay . hypersensitivity evaluation for f - 2 nanoemulsion containing vitamin k1 prepared according to example 2 method : the potential for the f - 2 vitamin k nanoemulsion ( lot # 111 - 1 - 24 ) to induce hypersensitivity was evaluated in guinea pigs following intraperitoneal ( ip ) sensitization then intravenous challenge with f - 2 . for a negative control , 0 . 9 % nacl solution ( normal saline ) was administered . as a positive control , bovine albumin ( bsa ) protein ( 2 . 5 mg / animal ) was injected . each f - 2 - treated animal received three ip sensitizing doses prior to being challenged with an intravenous injection of the f - 2 vitamin k1 nanoemulsion , normal saline , or bsa then observed for hypersensitivity reactions . results : none of the animals that were sensitized and challenged with the f - 2 nanoemulsion showed any hypersensitivity symptoms or reactions ; all animals in this group exhibited normal behavior . the negative control group also showed no hypersensitivity symptoms and exhibited normal behavior . in the positive control group , eight of the 10 animals exhibited behavior and symptoms consistent with allergic reactions : nose scratching , trembling , difficulty in breathing , twitching . six of the 8 positive control group animals died within one hour of the iv challenge . conclusion : the f - 2 nanoemulsion containing vitamin k1 and prepared according to this invention did not cause any hypersensitivity reactions and was non - allergenic in the test animals . bioequivalence demonstration for the f - 2 and f - 61 nanoemulsions containing vitamin k1 method : a mouse model was employed to compare the vitamin k1 plasma pharmacokinetic profiles of the f - 2 nanoemulsion prepared according to example 2 ( lot # 111 - 1 - 24 ) and pie - usp ( a generic version of aquamephyton ). each animal received a 0 . 1 ml tail vein injection of f - 2 nanoemulsion or pie - usp . blood samples were taken at 0 . 25 , 0 . 5 , 1 , 2 , 3 , 6 , 12 and 24 hours . for each time - point , blood samples from four mice were collected and analyzed for vitamin k1 concentration by an lc - ms / ms method . another two nanoemulsion compositions were prepared ( f - 61 ) to have the following compositions using the same method as described in example 1 . although they differed in vitamin k1 strength , the two f - 61 nanoemulsions had the same phospholipid - to - vitamin k weight ratio of 13 : 1 and oil concentration of 0 . 1 % by weight and possessed the same very high transparency ( t750 & gt ; 90 %) and small droplets (& lt ; 80 nm ). the two f - 61 nanoemulsions were also tested for their pharmacokinetic profiles in mice using the similar conditions as for f - 1 and were compared with pie - usp at the same vitamin k1 strengths ( 2 mg / ml , lot # 88 - 127 - ev and 10 mg / ml . lot # 88 - 130 - ev , both by hospira ) to determine bioequivalence ( fig5 ). results : fig4 shows the plasma pharmacokinetic profiles of f - 2 and fig5 the f - 61 nanoemulsions in comparison with their respective pie - usp reference drugs . conclusion : the overlapping plasma pharmacokinetic profiles for f - 2 and pie - usp at 2 mg / ml , f - 61 at 2 mg / ml and pie - usp at 2 mg / ml and f - 61 at 10 mg / ml and pie - usp at 10 mg / ml demonstrate that the nanoemulsions prepared according to this invention are bioequivalent to the phytonadione injectable emulsion , usp formulations of the same strength . physical stability of the f - 1 nanoemulsion prepared according to example 1 ( lot # 111 - 1 - 11 ) compared with the vitamin k1 composition disclosed in u . s . pat . no . 5 , 021 , 570 ( lot # 111 - 1 - 53 ) after freeze - thaw treatment a vitamin k emulsion was prepared according to u . s . pat . no . 5 , 021 , 570 having the following composition : the physical stability of these emulsions were tested and compared as follow : 1 . transfer 1 ml of an emulsion into a 2 ml glass vial . 4 . measure light transmittance of at 600 nm using a uv - visible spectrophotometer . 6 . thaw the emulsions and allow them to come to room temperature . conclusion : f - 1 nanoemulsion remained translucent , demonstrating that it retained its stability following a freeze - thaw cycle . in contrast , the prior art vitamin k1 emulsion produced according to u . s . pat . no . 5 , 021 , 570 was opaque , did not transmit light and was not stable after a freeze - thaw treatment . stability of vitamin k1 nanoemulsion compared with pie - usp under heat stress conditions two nanoemulsion compositions ( f - 10a and f - 10b ) were prepared with the following compositions according to the method described in example 1 . the f - 10a and f - 10b vitamin k1 nanoemulsions and the commercial drug product pie - usp ( hospira lot 81 - 345 - ev ) were autoclaved then placed into stability chambers at 40 ° c . and 60 ° c . after 1 and 2 - weeks in storage , each formulation was tested for phytonadione concentration and appearance . the results are shown in the tables below : conclusion : f - 10b exhibited a slightly greater recovery of phytonadione concentration than the pie - usp after 2 weeks at 60 ° c . the change in appearance in f - 10b was most likely due to oxidation of ascorbic acid under the extensive heat stress . preparation of nanoemulsions containing vitamin k having exceptionally high transparency and stability the following studies were conducted in a continuing effort to define the acceptable ranges for the phospholipid - to - vitamin k weight ratio and oil concentration for compositions having the desired droplet size (& lt ; 150 nm ), transparency ( t600 or t750 & gt ; 20 %) and stability ( comparable to or better than pie - usp ) objective : to investigate transparency , droplet size and viscosity in an emulsion with the phospholipid - to - vitamin k weight ratio less than 13 : 1 and / or oil concentration greater than 1 % by weight . the following compositions were prepared using a procedure similar to example 1 and tested for appearance , transparency and viscosity . conclusion : compositions with phospholipid - to - vitamin k weight ratio less than 13 : 1 and / or oil concentration greater than 1 % by weight are visually opaque , of high droplet size (& gt ; 150 nm ), low transparency and viscous ( the latter being unsuitable for injection ). objectives : to determine the acceptable ranges for phospholipid - to - vitamin k weight ratio and oil concentration used to achieve high transparency . the following compositions were prepared using a procedure similar to example 1 and tested for appearance , transparency and viscosity . * visual transparency ranking : 1 - 5 , 1 being the best ( clear ) and 5 being the worst ( opaque ). conclusion : compositions with phospholipid - to - vitamin k weight ratio at 13 : 1 , 14 : 1 , 15 : 1 , 16 : 1 , 17 : 1 and 18 : 1 and oil concentration of no more than 1 % achieved high transparency with t600 / 750 & gt ; 20 % for all or & gt ; 70 % for most of the samples . once the oil concentration reached 2 %, the compositions became opaque with t600 / 750 being & lt ; 20 % ( f48 , f - 49 , f - 50 , f - 51 , f - 52 to f - 53 ) and too viscous for injection ( f - 51 to f - 53 ). objectives : to determine and compare physical stability of f - 20 , f - 21 , f - 22 and f - 34 , f - 35 , f - 36 under freeze - thaw stress or after storage at 40 ° c . procedure : use the f - 20 , f - 21 , f - 22 and f - 34 , f - 35 , f - 36 prepared in study # 2 . apply freeze - thaw stress as follows : 1 . transfer 100 μl it of each formulation into an eppendorf vial . 2 . freeze at − 30 ° c . and thaw to room temperature . repeat for a total of three freeze - thaw cycles . transmittance for f - 22 and f - 36 after storage at 40 ° c . for 5 days conclusion : nanoemulsion compositions comprising phospholipid - to - vitamin k weight ratios of 13 : 1 , 14 : 1 and 15 : 1 and oil concentrations of no more than 1 % by weight are surprisingly transparent and physically stable against freeze - thaw and high temperature stress . objectives : to determine effects of soy lecithin type , benzyl alcohol , histidine , vitamin e , and nitrogen gas on stability of phytonadione in nanoemulsions comprising phospholipid - to - vitamin k weight ratio of 13 : 1 and oil concentration of 0 . 1 % by weight . the following compositions were prepared using a procedure similar to example 1 and tested for chemical stability of phytonadione in the nanoemulsion by measuring the recovered phytonadione by hplc analysis after the nanoemulsions were stored under heated conditions . composition % w / w f - 54 f - 55 f - 56 f - 57 f - 58 f - 59 f - 60 phytonadione 1 1 1 1 1 1 0 . 2 soybean oil 0 . 05 0 . 05 0 . 05 0 . 05 0 . 05 0 . 05 0 . 05 medium chain triglyceride 0 . 05 0 . 05 0 . 05 0 . 05 0 . 05 0 . 05 0 . 05 soy lecithin ( phospholipon 90g ) 13 0 13 13 13 13 13 soy lecithin ( lipoid s100 ) 0 13 0 0 0 0 0 benzyl alcohol 0 0 0 . 9 0 0 0 0 histidine 0 0 0 0 . 11 0 0 0 vitamin e 0 0 0 0 0 . 07 0 0 sucrose 10 10 10 10 10 10 10 wfi 75 . 9 75 . 9 75 75 . 79 75 . 83 75 . 9 76 . 7 n 2 gas in head space no no no no no yes no results phytonadione concentration by hplc analysis ( mg / g ) initial auto - 1 week @ 2 weeks @ 2 weeks @ id ( t0 ) claved 60 ° c . 60 ° c . 40 ° c . f - 54 phospholipon 90g 9 . 96 9 . 77 9 . 83 9 . 36 9 . 82 f - 55 lipoid s100 9 . 89 9 . 81 9 . 63 8 . 78 9 . 82 f - 56 benzyl alcohol 10 . 04 9 . 87 9 . 93 9 . 71 9 . 88 f - 57 histidine 10 . 04 9 . 94 10 . 08 9 . 88 10 . 03 f - 58 vitamin e 9 . 92 9 . 70 9 . 64 9 . 43 9 . 78 f - 59 n2 10 . 18 9 . 85 9 . 88 9 . 67 10 . 36 f - 60 2 mg / g 2 . 07 1 . 99 1 . 95 1 . 71 2 . 01 f - 1 * 2 mg / g 1 . 93 1 . 86 1 . 64 1 . 24 1 . 88 pie - usp ** 2 mg / ml 2 . 02 2 . 04 2 . 07 2 . 02 na phytonadione recovery (% over t0 ) auto - 1 week 2 weeks 2 weeks id t0 claved 60 ° c . 60 ° c . 40 ° c . f - 54 phospholipon 90g 100 98 . 1 98 . 7 94 . 0 98 . 6 f - 55 lipoid s100 100 99 . 2 97 . 4 88 . 8 99 . 3 f - 56 benzyl alcohol 100 98 . 3 98 . 9 96 . 7 98 . 4 f - 57 histidine 100 99 . 0 100 . 3 98 . 3 99 . 9 f - 58 vitamin e 100 97 . 7 97 . 2 95 . 1 98 . 6 f - 59 n2 100 96 . 8 97 . 1 95 . 1 101 . 8 f - 60 2 mg / g 100 96 . 2 94 . 3 82 . 4 97 . 1 f - 1 2 mg / g 100 96 . 4 85 . 1 63 . 9 97 . 5 pie - usp 2 mg / ml 100 100 . 9 102 . 5 100 . 3 na * as in example 1 . ** 2 mg / ml phytonadione injectable emulsion , usp , from hospira lot 81 - 345 - ev 1 . histidine is beneficial for phytonadione stability . 2 . f - 57 ( with histidine ) has stability that is comparable to pie - usp . 3 . different types of soy lecithin ( from different sources ) can be used to prepare the nanoemulsions with comparable properties . preparation of nanoemulsions comprising a phospholipid - to - vitamin k weight ratio of 13 : 1 , an oil concentration of 0 . 1 % and other phospholipids , oil , cryoprotectant and stabilizers the contents of the articles , patents , and patent applications , and all other documents and electronically available information mentioned or cited herein , are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference . applicants reserve the right to physically incorporate into this application any and all materials and information from any such articles , patents , patent applications , or other documents . the inventions illustratively described herein may suitably be practiced in the absence of any element or elements , limitation or limitations , not specifically disclosed herein . thus , for example , the terms “ comprising ”, “ including ,” containing ”, etc . shall be read expansively and without limitation . additionally , the terms and expressions employed herein have been used as terms of description and not of limitation , and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof , but it is recognized that various modifications are possible within the scope of the invention claimed . thus , it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features , modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art , and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims . the invention has been described broadly and generically herein . each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention . this includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus , regardless of whether or not the excised material is specifically recited herein . in addition , where features or aspects of the invention are described in terms of markush groups , those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the markush group .
in certain embodiments , this invention sets forth compositions , methods , and uses regarding a nanoemulsion composition that comprises a fat - soluble vitamin k and can therapeutically replace phytonadione injectable emulsion , usp .